Marketing & Sales

Novartis’ Sandoz to buy Aspen’s Japanese business in $441m deal

Novartis division Sandoz has signed a binding agreement to acquire Aspen Global’s Japanese business in a deal valued at around €400m ($441m).

Samsung Bioepis enters into commercialisation agreement for next-generation biosimilar candidates

Samsung Bioepis Co., Ltd. announced today that it has entered into a new commercialization agreement with Biogen (Nasdaq: BIIB) for two biosimilar candidates under development by Samsung Bioepis, SB11 (ranibizumab) and SB15 (aflibercept), in the United States (US), Canada, Europe, Japan, and Australia.

AstraZeneca to sell anti-psychotic medicine rights in Europe and Russia for $239m

AstraZeneca has signed an agreement to sell Seroquel medicine rights in Europe and Russia to Cheplapharm Arzneimittel for around $239m.

Bavarian Nordic to buy GSK’s rabies and tick-borne encephalitis vaccines

Denmark-based Bavarian Nordic has signed an agreement to acquire rabies and tick-borne encephalitis (TBE) vaccines from GlaxoSmithKline in a deal valued at around €796m ($888m).

Acino to buy Takeda’s select OTC and prescription pharmaceutical assets for $200m

Swiss pharmaceutical company Acino has agreed to acquire Takeda’s select over-the-counter (OTC) and prescription pharmaceutical assets in multiple Near East, Middle East and Africa (NEMEA) countries for a total value of more than $200m.

Servier acquires lymphoma drug Pixuvri from CTI BioPharma

French pharma company Servier has acquired cancer drug Pixuvri (pixantrone) from US-based CTI BioPharma for an undisclosed price in a move to strengthen its oncology portfolio.

Amgen to buy Celgene’s psoriasis drug Otezla for £10.9bn

US-based Amgen has agreed to acquire Celgene’s psoriasis drug Otezla (apremilast) and certain related assets and liabilities for $13.4bn (£10.9bn) in cash.

Bayer to offload animal health business to Elanco for £6.27bn

German pharma giant Bayer has agreed to offload its animal health unit to Elanco Animal Health for $7.6bn (£6.27bn) in a stock-cum-cash deal, in a move to focus on its life sciences business.

Pfizer announces closing of JV with GSK to create premier global consumer healthcare company

Pfizer announced the closing of its joint venture (JV) with GlaxoSmithKline to combine the parties’ respective consumer healthcare businesses to create the world’s largest over-the-counter (OTC) business with robust iconic brands.